Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

CC Zielinski; I Lang; M Inbar; Z Kahan; Richard Greil; S Beslija; SM Stemmer; Z Zvirbule; GG Steger; B Melichar; T Pienkowski; D Sirbu; L Petruzelka; A Eniu; B Nisenbaum; M Dank; R Anghel; D Messinger; T Brodowicz

Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

CC Zielinski, I Lang, M Inbar, Z Kahan, Richard Greil, S Beslija, SM Stemmer, Z Zvirbule, GG Steger, B Melichar, T Pienkowski, D Sirbu, L Petruzelka, A Eniu, B Nisenbaum, M Dank, R Anghel, D Messinger, T Brodowicz

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	S263-S264
Journal	EUROPEAN JOURNAL OF CANCER
Volume	51
Publication status	Published - 2015
Event	European Cancer Congress - Vienna, AUSTRIA Duration: 1 Jan 2015 → …

Cite this

Zielinski, CC., Lang, I., Inbar, M., Kahan, Z., Greil, R., Beslija, S., Stemmer, SM., Zvirbule, Z., Steger, GG., Melichar, B., Pienkowski, T., Sirbu, D., Petruzelka, L., Eniu, A., Nisenbaum, B., Dank, M., Anghel, R., Messinger, D., & Brodowicz, T. (2015). Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). EUROPEAN JOURNAL OF CANCER , 51, S263-S264.

Zielinski, CC ; Lang, I ; Inbar, M et al. / Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). In: EUROPEAN JOURNAL OF CANCER 2015 ; Vol. 51. pp. S263-S264.

@article{198caac5595e4703a41be88c61d752b0,

title = "Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)",

author = "CC Zielinski and I Lang and M Inbar and Z Kahan and Richard Greil and S Beslija and SM Stemmer and Z Zvirbule and GG Steger and B Melichar and T Pienkowski and D Sirbu and L Petruzelka and A Eniu and B Nisenbaum and M Dank and R Anghel and D Messinger and T Brodowicz",

year = "2015",

language = "English",

volume = "51",

pages = "S263--S264",

journal = "EUROPEAN JOURNAL OF CANCER ",

issn = "0959-8049",

publisher = "Elsevier ",

note = "European Cancer Congress ; Conference date: 01-01-2015",

}

Zielinski, CC, Lang, I, Inbar, M, Kahan, Z, Greil, R, Beslija, S, Stemmer, SM, Zvirbule, Z, Steger, GG, Melichar, B, Pienkowski, T, Sirbu, D, Petruzelka, L, Eniu, A, Nisenbaum, B, Dank, M, Anghel, R, Messinger, D & Brodowicz, T 2015, 'Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)', EUROPEAN JOURNAL OF CANCER , vol. 51, pp. S263-S264.

Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). / Zielinski, CC; Lang, I; Inbar, M et al.
In: EUROPEAN JOURNAL OF CANCER , Vol. 51, 2015, p. S263-S264.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

AU - Zielinski, CC

AU - Lang, I

AU - Inbar, M

AU - Kahan, Z

AU - Greil, Richard

AU - Beslija, S

AU - Stemmer, SM

AU - Zvirbule, Z

AU - Steger, GG

AU - Melichar, B

AU - Pienkowski, T

AU - Sirbu, D

AU - Petruzelka, L

AU - Eniu, A

AU - Nisenbaum, B

AU - Dank, M

AU - Anghel, R

AU - Messinger, D

AU - Brodowicz, T

PY - 2015

Y1 - 2015

M3 - Abstract (Journal)

SN - 0959-8049

VL - 51

SP - S263-S264

JO - EUROPEAN JOURNAL OF CANCER

JF - EUROPEAN JOURNAL OF CANCER

T2 - European Cancer Congress

Y2 - 1 January 2015

ER -

Zielinski CC, Lang I, Inbar M, Kahan Z, Greil R, Beslija S et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). EUROPEAN JOURNAL OF CANCER . 2015;51:S263-S264.